India Ditches Local Trials—Rocketing Foreign Vaccines to Beat COVID‑23
Picture this: the world’s second‑largest country, brimming with 1.3 billion people, decides that the “trial‑time” hassle is a thing of the past. The legislature pulls the plug on all local testing for vaccines that already proved solid elsewhere. Why? Because India’s second wave is a full‑blown tornado—tens of thousands dead, and the death toll just eclipsed any other month ever.
Current Vaccination Reality
- AstraZeneca (made locally by the Serum Institute)
- Covaxin (home‑grown by Bharat Biotech)
- Russia’s Sputnik V has just joined the squad
But the numbers? Let’s break it down:
- Only ~3 % of the population is fully vaccinated—lowest among the top ten COVID‑hit countries.
- Survivor sirens: 98 % of the population is still vulnerable.
Where Are the Doses?
India’s arrows are sputtering in the vast market. The government is in talks with Pfizer, Johnson & Johnson, and Moderna for an “earliest possible” supply, but the world’s stocks are low.
Back in April, India promised a fast‑track passport for foreign shots, only to get hit with a procedural pin‑point: each vaccine had to go through local trials. Now, the ministry says: “We’re scrapping that requirement for established vaccines.” They’re encouraging international manufacturers to “make in India— for India and the world.”
Crunching the Numbers
Risky headline stats:
- 211,298 new infections on Thursday—world’s highest daily spike, though half of previous May’s records.
- Total cases: 27.37 million.
- Deaths: 315,235 (though one hot take suggests that if we counted untested victims, the real toll might be sky‑high).
State vs. Federal Tug‑of‑War
At the state level, some are launching global tenders, calling out Pfizer and Moderna. However, the vaccine giants say they’re playing a “federal only” game.
To wrap it up, the government’s candid trip‑tych:
“Global tenders not yielding supplies simply confirms what we told the states from the very start—vaccines are scarce, and snagging them on a whim is a tall order.”
In the end, India’s bold move to forgo local trials is a sign that the country has decided: it’s time to bring the big guns—global vaccines—directly to the front lines.
